2015 American Transplant Congress
Pharmacokinetics of Tacrolimus (TAC) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…2015 American Transplant Congress
Immunologic Outcomes in Elderly Kidney Transplant Recipients
Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany.
BACKGROUND: Only few data are available about immunologic outcomes of elderly kidney transplant recipients (KTR).PATIENTS AND METHODS: This retrospective long-term observational study included all adult…2015 American Transplant Congress
Quality of Life in Elderly Kidney Transplant Recipients over 70 Years of Age
Department of Medicine, University of Minnesota, Minneapolis, MN.
Objectives:Kidney transplantation in the elderly provides a survival advantage in comparison with those who remain on dialysis. However, the impact of transplantation on the quality…2015 American Transplant Congress
Octogenarian Kidney Transplant Recipients: A Single Center Experience
University of Maryland Medical Center, Baltimore, MD.
Background: Elderly patients are the fastest growing population requiring kidney transplantation internationally. Previous studies have shown a survival benefit for kidney transplantation when compared to…2015 American Transplant Congress
Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
The use and choice of induction immunosuppression in elderly kidney recipients remains unresolved. Alemtuzumab has been associated with a higher risk of death and graft…
- « Previous Page
- 1
- …
- 15
- 16
- 17